Anbio Biotechnology Class A Ordinary Shares
NNNN · NASDAQ
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -60% | 60% | 19.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 84.6% | 66.9% | 42.8% | 58.7% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | $0 | $0 | $0 |
| % Margin | -68.6% | 61.5% | 14.8% | 46.5% |
| Other Income/Exp. Net | $0 | -$0 | $0 | $0 |
| Pre-Tax Income | -$0 | $0 | $0 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | $0 | $0 | $0 |
| % Margin | -52.4% | 61.5% | 20.1% | 49.7% |
| EPS | -0.031 | 0.092 | 0.019 | 0.039 |
| % Growth | -134.1% | 391.4% | -51.9% | – |
| EPS Diluted | -0.031 | 0.092 | 0.019 | 0.039 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | $0 | $0 | $0 |
| % Margin | -52.4% | 61.5% | 20.2% | 50% |